Keros Therapeutics Reports Second Quarter 2024 Financial Results
Keros Therapeutics, Inc. - common stock (KROS)
Company Research
Source: GlobeNewswire
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended June 30, 2024. “Keros continued to build upon the progress of all programs across our pipeline in the second quarter of 2024, as evidenced by our recent positive regulatory and data updates from the elritercept (KER-050) program,” said Jasbir S. Seehra, Ph.D., Chair and Chief Executive Officer. “We continue to be excited by the strong enrollment activity we have seen to date in our Phase 2 clinical trial of cibotercept (KER-012) in patients with pulmonary arterial hypertension and look forward to completing enrollment of that trial in the fourth quar
Show less
Read more
Impact Snapshot
Event Time:
KROS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KROS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KROS alerts
High impacting Keros Therapeutics, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
KROS
News
- Keros Therapeutics, Inc. (NASDAQ: KROS) is now covered by analysts at Guggenheim. They set a "buy" rating and a $96.00 price target on the stock.MarketBeat
- Keros Therapeutics, Inc. (NASDAQ: KROS) had its price target lowered by analysts at Bank of America Co. from $81.00 to $76.00. They now have a "buy" rating on the stock.MarketBeat
- Keros Therapeutics Announces Updated Time of Presentation at 2024 Cantor Global Healthcare ConferenceGlobeNewswire
- Keros Therapeutics Announces Update on Enrollment in the Phase 2 TROPOS TrialGlobeNewswire
- Keros Therapeutics Announces Participation at Upcoming Healthcare ConferencesGlobeNewswire
KROS
Earnings
- 8/7/24 - Miss
KROS
Sec Filings
- 9/3/24 - Form 8-K
- 8/28/24 - Form 8-K
- 8/15/24 - Form 4
- KROS's page on the SEC website